Anne Sofie Bjerrum

Anne Sofie Bjerrum

Auto-generated profile, based on publicly available information

Anne Sofie Bjerrum

Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2013 in Medical Education
Verified
Journal Article
Closed access
PDF file
ABAnne Sofie Bjerrum
Anne Sofie Bjerrum
OHOle Hilberg
Ole Hilberg
TGTamara van Gog
Tamara van Gog
PCPeder Charles
Peder Charles
BEBerit Eika
Berit Eika

9 June 2014 in Medical Education
Verified
Journal Article
Closed access
PDF file
ABAnne Sofie Bjerrum
Anne Sofie Bjerrum
BEBerit Eika
Berit Eika
PCPeder Charles
Peder Charles
OHOle Hilberg
Ole Hilberg

1 January 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
ABAnne Sofie Bjerrum
Anne Sofie Bjerrum
TSTina Skjold
Tina Skjold
JSJohannes Martin Schmid
Johannes Martin Schmid

1 January 2016 in Medical Education Online
Verified
Journal Article
Open access
PDF file
ABAnne Sofie Bjerrum
Anne Sofie Bjerrum
BEBerit Eika
Berit Eika
PCPeder Charles
Peder Charles
OHOle Hilberg
Ole Hilberg
Distributed practice. The more the merrier? A randomised bronchoscopy simulation study

11 June 2025 in Respiratory Medicine
Verified
Journal Article
Open access
SHSusanne Hansen
Susanne Hansen
KHKjell Erik Julius Håkansson
Kjell Erik Julius Håkansson
MSMarianne Baastrup Soendergaard
Marianne Baastrup Soendergaard
ABAnne-Sofie Bjerrum
Anne-Sofie Bjerrum
JSJohannes Martin Schmid
Johannes Martin Schmid
CPCeleste Porsbjerg
Celeste Porsbjerg
Randomized clinical trials have demonstrated that dupilumab reduces exacerbations and maintenance oral corticosteroids (mOCS) use in patients with uncontrolled and severe asthma. However, evidence in real-life settings is limited. This study aimed to evaluate the proportion of patients achieving a clinical response and remission after treatment with dupilumab and identify predictors of response. We conducted a prospective observational study involving 203 severe asthma patients from the nationwide Danish Severe Asthma Register treated with dupilumab for 12 months. Clinical response to treatment was defined as a 50 % reduction in exacerbations and/or a 50 % reduction in mOCS dose. Clinical remission required meeting all the following criteria: complete cessation of exacerbations, no mOCS use, an Asthma Control Questionnaire (ACQ-6) score 80 % of the predicted value. Predictors of treatment response were identified in a multivariate logistic regression model. After 12 months of dupilumab treatment, 91 % of patients demonstrated a clinical response, and 30 % achieved clinical remission. All patients experienced fewer exacerbations, while patients with a clinical response and those achieving remission also exhibited significant improvements in mOCS dose reduction, FEV1 %, and ACQ-6 score. Predictors of remission included higher baseline fractional exhaled nitric oxide [OR = 3.82 (95 % CI: 0.90, 16.17)], lower body mass index [OR = 0.82 (95 % CI: 0.71, 0.93) for one unit increase], and the absence of allergic rhinitis [OR = 0.30 (95 % CI: 0.08, 1.11)]. In this real-life setting, involving over 200 patients treated with dupilumab for 12 months, 91 % had a clinical response, and 30 % of patients achieved clinical remission. These findings highlight dupilumab's potential in improving outcomes for severe asthma patients.

18 February 2015 in Medical Education
Verified
Journal Article
Closed access
PDF file
ABAnne Sofie Bjerrum
Anne Sofie Bjerrum
AMAnne Mette Morcke
Anne Mette Morcke